BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Korea's Neurophet & InRAD to establish global standards for Alzheimer's disease and dementia data

September 3, 2025 | News

Neurophet's AI-based brain imaging analysis solutions to support global standardisation of Alzheimer's and other dementia-related data



Neurophet, a South Korea-based artificial intelligence (AI) solution startup for brain disorders diagnosis and treatment has signed a Memorandum of Understanding (MoU) with the International Registry for Alzheimer's Disease and Other Dementias Foundation (InRAD) to accelerate global standardisation of Alzheimer's and dementia-related data.

Through this agreement, Neurophet and InRAD aim to strengthen their collaboration to help establish globally harmonized standards for Alzheimer's disease and other dementias real-world data. The partnership also seeks to enable the seamless integration of AI-based neuroimaging technologies into the broader real-world data landscape, removing one of the key practical barriers to evidence generation - namely, the lack of coordinated approaches - while acknowledging the wider adoption of these technologies in everyday clinical practice.

The partnership will focus on key initiatives including:

- Enhancing clinical workflows involving MRI and PET analysis
- Collecting and aggregating clinical imaging and quantitative data
- Validating clinical utility of AI-based analysis solutions
- Developing joint research and education programmes

Neurophet's flagship products — Neurophet AQUA AD, an Alzheimer's Disease Treatment Prescription/Treatment Effect and Side Effect Monitoring Software; and Neurophet SCALE PET, a PET Image Quantitative Analysis Software; and Neurophet AQUA, a Brain MRI Analysis Software — will be available for utilization in this collaboration.

InRAD is a free at the point-of-use registry that enables the collection of real-world data to further understanding about Alzheimer's disease, and in the future, other dementias and to support clinical management. The registry is coordinated by the independent International Registry for Alzheimer's Disease and Other Dementias Foundation, a health-related not-for-profit entity incorporated in the Netherlands. The registry platform will launch later in 2025, providing a secure, regionally compliant, Azure cloud-based registry platform and governance package.